Advance in studies on pharmacological activity of coptisine hydrochloride

Zhongguo Zhongyao Zazhi

Volumn 38, Issue 17, 2013, Pages 2750-2754

  Zhang, Zhi Hui ^a   Deng, An Jun ^a   Yu, Jin Qian ^a   Li, Zhi Hong ^a   Wu, Lian Qiu ^a   Wang, Wen Jie ^a   Qin, Hai Lin ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Advance in studies; Coptisine hydrochloride; Pharmacological activity

Indexed keywords

ALKALOID; AMINE OXIDASE (FLAVIN CONTAINING); COPTISINE; PROTOBERBERINE; QUATERNARY AMMONIUM DERIVATIVE;

ANTIFUNGAL ACTIVITY; CELL PROLIFERATION; ENZYME INHIBITION; HEART PROTECTION; NONHUMAN; OSTEOCLAST; PAPAVERACEAE; PHARMACOLOGY; PUBLISHING; RANUNCULACEAE; REVIEW; SCIENTIFIC LITERATURE; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; BERBERINE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; HUMANS;

EID: 84890364070     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20131703     Document Type: Review

References (46)

1. Nagatsu T, Yamamoto T, Harada M. Purification and properties of human brain mitochondrial monoamine oxidase [J]. Enzymologia, 1970, 39: 15.
2. Tipton K F, O'Carroll A M, McCrodden J M. The catalytic behavior of monoamine oxidase [J]. J Neural Transm (Suppl), 1987, 23: 25.
3. Severina I S. "Mechanism of selective inhibition by clorgyline and deprenyl of the possible nature of its form A and B" in monoamine oxidase: structure, function, and altered functions [M]. New York: Academic Press, 1979: 169.
4. Deniker P. The search for new antidepressants and related drugs, in monoamine oxidase and diseases, prospects for therapy with reversible inhibitors [M]. New York: Academic Press, 1984: 3.
5. Ro J S, Lee S S, Lee K S, et al. Inhibition of type A monoamine oxidase by coptisine in mouse brain [J]. Life Sci, 2001, 70: 639.
6. Lee S S, Kai M, Lee M K. Effects of natural isoquinoline alkaloids on monoamine oxidase activity in mouse brain: inhibition by berberine and palmatine [J]. Med Sci Res, 1999, 27: 749.
7. Lee M K, Lee K S, Kim H S, et al. Inhibitory effects of coptisine on monoamine oxidase activity [J]. Nat Prod Sci, 2000, 6: 70.
8. Lee S S, Yoon-Choi H S, Kim E I, et al. Inhibition of monoamine oxidase by higenamine [J]. Med Sci Res, 1999, 27: 71.
9. Ross R. Atherosclerosis-an inflammatory disease [J]. N Engl J Med, 1999, 340: 115.
10. Tanabe H, Suzuki H, Nagatsu A, et al. Selective inhibition of vascular smooth muscle cell proliferation by coptisine isolated from Coptis Rhizoma, one of the crude drugs composing Kampo medicines Unsei-in [J]. Phytomedicine, 2006, 13: 334.
11. Zhan Y H, Fang L H, Ku B S. Fangchinoline inhibits rat aortic vascular smooth muscle cell proliferation and cell cycle progression through inhibition of ERK1/2 activation and c-fos expression [J]. Biochem Pharmacol, 2003, 66: 1853.
12. Ferri, N, Yokoyama K, Sadilek M, et al. Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation [J]. Br J Pharmacol, 2003, 138: 811.
13. Kobayashi S, Mimura Y, Notoya K, et al. Antiproliferative effects of the traditional Chinese medicine Shimotsu-to, its component cnidium rhizoma and derived compounds on primary cultures of mouse aorta smooth muscle cells [J]. Jpn J Pharmcol, 1992, 60: 397.
14. Alcocer F, Whitley D, Salazar-Gonzalez J F, et al. Quercetin inhibits human vascular smooth muscle cell proliferation and migration [J]. Surgery, 2002, 131: 198.
15. Shin J S, Kim E I, Kai M, et al. Inhibition of dopamine biosynthesis by protoberberine alkaloids in PC12 cells [J]. Neurochem Res, 2000, 25: 363.
16. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation [J]. Bone, 2007, 40: 251.
17. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors [J]. J Exp Med, 1999, 190(12): 1741.
18. Boyle W J, Simonet W S, Lacey D L. Osteoclast differentiation and activation [J]. Nature, 2003, 423: 337.
19. Hofbauer L C, Khosla S, Dunstan C R, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption [J]. J Bone Miner Res, 2000, 15: 2.
20. Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function [J]. Endocrinology, 2000, 141: 3478.
21. Ji W L, Ayumi I, Shin-ichi H, et al. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells [J]. J Nat Med, 2012, 66: 8.
22. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families [J]. Endocr Rev, 1999, 20: 345.
23. Chang E J, Kim H J, Ha J, et al. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4 [J]. J Cell Sci, 2007, 120: 166.
24. Tanabe H, Suzuki H, Inoue M, et al. Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells [J]. Biochem Pharmacol, 2005, 70: 1176.
25. Hiroka S, Hiroki T, Hajinme M, et al. Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine [J]. Biol Pharm Bull, 2010, 33: 677.
26. Batovska D, Parushev S, Slavova A, et al. Study on the substituents'effects of a series of synthetic chalcones against the yeast Candida albicans [J]. Eur J Med Chem, 2007, 42: 87.
27. 2006, 37(2): 125.
28. 2007, 42(5): 349.
29. Kong W J, Zhao X H, Xiao X H, et al. Investigation of the anti-fungal activity of coptisine on Candida albicans growth by microcalorimetry combined with principal component analysis [J]. J App Micro, 2009, 107: 1072.
30. Iwasa K, Kamigauchi M, Ueki M, et al. Antibacterial activity and structure-activity relationships of berberine analogs [J]. Eur J Med Chem, 1996, 31: 469.
31. Donlan R M, Costerton J W. Biofilms: survival mechanisms of clinically relevant microorganisms [J]. Clin Microbiol Rev, 2002, 15: 167.
32. 2007, 18(12): 3013.
33. Korkmaz S, Radovits T, Barnucz E, et al. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury [J]. Circulation, 2009, 120: 677.
34. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice [J]. Circulation, 2004, 109: 2234.
35. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases [J]. Am J Physiol Heart Circ Physiol, 2011, 301: H287.
36. Chandra S, Romero M, Shatanawi A, et al. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway [J]. Br J Pharmacol, 2012, 165: 506.
37. Noma K, Goto C, Nishioka K, et al. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness [J]. J Am Coll Cardiol, 2007, 49: 698.
38. Chau V Q, Salloum F N, Hoke N N, et al. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway [J]. Am J Physiol Heart Circ Physiol, 2011, 300: H2272.
39. 2+ currents in cardiac myocytes [J]. Am J Physiol Heart Circ Physiol, 2005, 288: H650.
40. Gong L L, Fang L H, Wang S B, et al. Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats [J]. Atherosclerosis, 2012, 222: 50.
41. Hirano H, Osawa E, Yamaoka Y, et al. Gastric-mucous membrane protection activity of coptisine derivatives [J]. Biol Pharm Bull, 2001, 24: 1277.
42. 2007, 22(6): 713.
43. Maria L C, Carlo B, Andrea M, et al. Cytotoxicity evaluation of natural coptisine and synthesis of coptisine from berberine [J]. Farmaco, 2001, 56: 403.
44. 2011, 27(5): 610.
45. 2011, 42(4): 640.
46. Wu J B, Lei F, Cui X J, et al. Design, synthesis and multidrug resistance reversal activity evaluation of 8-oxocoptisine derivatives [J]. Med Chem, 2012, 8: 742.